T. Amaral

发表

Cutaneous melanoma attributable to UVR exposure in Denmark and Germany.

C. Garbe, D. Whiteman, S. Gandini, 2021, European journal of cancer.

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment

I. Fernandes, L. Costa, T. Amaral, 2012, Prostate cancer.

Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy

C. Garbe, U. Leiter, T. Amaral, 2017, Reviews in Endocrine and Metabolic Disorders.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Acquired resistance mechanisms to immunotherapy.

C. Garbe, T. Amaral, 2016, Annals of translational medicine.

Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy

J. Moltz, S. Afat, S. Gatidis, 2022, Cancers.

Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms

D. Rimm, K. Ikenberg, J. Wilmott, 2022, EBioMedicine.

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?

C. Garbe, P. Martus, A. Forschner, 2020, Cancers.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade

C. Garbe, G. Pawelec, S. Hadrup, 2022, Frontiers in Immunology.

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

C. Berking, S. Haferkamp, A. Gesierich, 2020, Journal for ImmunoTherapy of Cancer.

Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.

C. Garbe, A. Forschner, T. Amaral, 2017, European journal of cancer.

Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.

A. Hauschild, F. Egberts, U. Reinhold, 2020, European Journal of Cancer.

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

J. Utikal, C. Berking, A. Hauschild, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone microenvironment signals in osteosarcoma development

E. Álava, A. Abarrategi, A. Alfranca, 2015, Cellular and Molecular Life Sciences.

S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow‐up, prevention and occupational disease

C. Berking, J. Becker, M. Heppt, 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry

C. Garbe, A. Forschner, U. Leiter, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti‐PD‐1 therapy

C. Garbe, A. Forschner, S. Biskup, 2022, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Non-melanoma skin cancer: new and future synthetic drug treatments

C. Garbe, T. Amaral, 2017, Expert opinion on pharmacotherapy.

Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns

D. Presser, C. Garbe, U. Leiter, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicators

C. Berking, J. Becker, C. Garbe, 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy

C. Garbe, G. Pawelec, P. Terheyden, 2021, Journal for ImmunoTherapy of Cancer.

Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.

C. Garbe, T. Sinnberg, H. Niessner, 2019, European journal of cancer.

Targeting tumor-resident mast cells for effective anti-melanoma immune responses.

H. Rammensee, S. Kaesler, T. Volz, 2019, JCI insight.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.

A. Lallas, I. Zalaudek, A. Hauschild, 2020, European journal of cancer.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.

Giovanni Pellacani, Josep Malvehy, Axel Hauschild, 2019, European journal of cancer.

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.

C. Garbe, M. Levesque, C. Krepler, 2017, European journal of cancer.

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients

C. Garbe, C. Schroeder, O. Riess, 2020, Cancers.

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

C. Garbe, M. Levesque, C. Krepler, 2017, European journal of cancer.

A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma

Adria Font Calvarons, K. Nikolaou, S. Faby, 2021, Journal for ImmunoTherapy of Cancer.

Immunotherapy in managing metastatic melanoma: which treatment when?

C. Garbe, T. Amaral, Francisco Meraz-Torres, 2017, Expert opinion on biological therapy.

Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR)

C. Garbe, A. Forschner, T. Eigentler, 2017, Journal of Cancer Research and Clinical Oncology.

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

C. Garbe, P. Martus, A. Forschner, 2021, Cancers.

Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy.

S. Afat, B. Klumpp, T. Eigentler, 2021, Academic radiology.

Whole-Body Soft-Tissue Lesion Tracking and Segmentation in Longitudinal CT Imaging Studies

Sergios Gatidis, Alessa Hering, Jan Moltz, 2021, MIDL.

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

D. Schadendorf, G. Madonna, D. Mallardo, 2020, Journal for ImmunoTherapy of Cancer.

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma

C. Garbe, A. Forschner, U. Leiter, 2020, Cancers.

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma

C. Garbe, C. Schroeder, O. Riess, 2020, Cancers.

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study

C. Garbe, F. Meier, T. Sinnberg, 2020, Neuro-oncology advances.

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

J. Utikal, C. Berking, A. Gesierich, 2019, Journal of Immunotherapy for Cancer.

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade

C. Garbe, G. Pawelec, P. Terheyden, 2019, PloS one.

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

C. Garbe, Chung-Ting Han, P. Martus, 2019, Journal of Immunotherapy for Cancer.

Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.

G. Tabatabai, C. Garbe, M. Tatagiba, 2019, Immunotherapy.

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts

J. Utikal, A. Hauschild, D. Schadendorf, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma

C. Garbe, T. Amaral, N. Nouri, 2016, Expert review of anticancer therapy.

The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012

I. Fernandes, L. Costa, T. Amaral, 2013, ISRN hepatology.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Late recurrence of melanoma after 10 years – Is the course of the disease different from early recurrences?

C. Garbe, U. Leiter, U. Keim, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036.

C. Garbe, D. Whiteman, S. Gandini, 2021, European journal of cancer.

Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).

A. Eggermont, A. Forschner, U. Leiter, 2022, European journal of cancer.

How to use neoadjuvant medical treatment to maximize surgery in melanoma

C. Garbe, T. Amaral, I. Tampouri, 2018, Expert review of anticancer therapy.

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

D. Schadendorf, S. Ugurel, B. Becher, 2023, Med.

Time trends in incidence and mortality of cutaneous melanoma in Germany

C. Garbe, P. Martus, A. Katalinic, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase

A. Hauschild, B. Schilling, V. Glutsch, 2020, Acta dermato-venereologica.

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy

C. Garbe, C. Schroeder, S. Ossowski, 2022, Journal of Cancer Research and Clinical Oncology.

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy

A. Forschner, U. Leiter, T. Sinnberg, 2023, American Journal of Clinical Dermatology.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma

C. Garbe, G. Pawelec, M. Claassen, 2023, Journal for ImmunoTherapy of Cancer.

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases

D. Rimm, C. Garbe, M. Röcken, 2023, EBioMedicine.

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

J. Utikal, D. Schadendorf, W. Sondermann, 2023, Nature Cancer.

German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – long version of the update 2023

M. Weichenthal, A. Hauschild, M. Flaig, 2023, EJC Skin Cancer.

Prognosis in stage II melanoma of the head and neck depends on the histological subtype

A. Forschner, U. Leiter, L. Flatz, 2023, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment

I. Fernandes, L. Costa, T. Amaral, 2012, Prostate cancer.

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

A. Hauschild, D. Schadendorf, P. Ascierto, 2023, Nature Medicine.

Real‐world outcomes using PD‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

S. Haferkamp, K. Kähler, W. Peitsch, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

'Corrigendum to "Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins" [Eur J Cancer 81 (August 2017) 203-205]'.

C. Garbe, A. Forschner, T. Amaral, 2017, European Journal of Cancer.

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy

H. Niessner, T. Amaral, Sarah Plöger, 2024, Journal of experimental & clinical cancer research : CR.